A single dose of CBD significantly reduced multiple markers of lung inflammation in a mouse model of acute lung injury, and the effect worked through adenosine A2A receptor signaling.
Read this if you are interested in CBD's anti-inflammatory potential for lung conditions.
All anti-inflammatory effects of CBD were abolished when the A2A receptor was blocked
What the researchers found
Researchers induced acute lung injury in mice using LPS (a bacterial toxin) and administered a single 20 mg/kg dose of CBD beforehand. CBD decreased neutrophil migration into the lungs, reduced protein leakage (indicating less tissue damage), lowered the enzyme myeloperoxidase (a marker of neutrophil activity), and reduced pro-inflammatory cytokines (TNF and IL-6) and chemokines (MCP-1 and MIP-2).
These anti-inflammatory effects persisted at 1, 2, and 4 days after injury. Critically, when researchers blocked the adenosine A2A receptor with a selective antagonist, all of CBD's anti-inflammatory effects were abolished, confirming this receptor as the mechanism.
Why it matters
Acute lung injury is a serious inflammatory condition with no established pharmacological treatment beyond supportive care. This study identified CBD as a potent anti-inflammatory agent in this context and pinpointed the specific receptor mechanism, which could guide development of targeted treatments.
The numbers in context
Single dose of 20 mg/kg CBD. Anti-inflammatory effects measured at days 1, 2, and 4 post-injury. CBD reduced neutrophils, albumin, myeloperoxidase, TNF, IL-6, MCP-1, and MIP-2. All effects abolished by adenosine A2A receptor antagonist.
How the study worked
Mouse model of acute lung injury induced by LPS. CBD (20 mg/kg) was administered before injury. Outcomes measured included leukocyte migration, albumin concentration in bronchoalveolar lavage fluid, myeloperoxidase activity, and cytokine/chemokine levels. The adenosine A2A receptor antagonist ZM241385 was used to test the mechanism.
What this study cannot tell us
This was a mouse study, and the LPS model of acute lung injury does not perfectly replicate the human condition. CBD was given before injury (pre-treatment), which differs from the clinical scenario where treatment begins after injury occurs. Dosing may not translate directly to human applications.
How to read the evidence
Animal study with a clear mechanism identified; preliminary evidence that needs human validation.
When this study was published
Published in 2012. CBD anti-inflammatory research has expanded significantly since, including interest during the COVID-19 pandemic.
The bigger picture
This study contributes to understanding CBD's anti-inflammatory mechanisms beyond the endocannabinoid system. The adenosine A2A receptor pathway is a well-established anti-inflammatory signaling system, and CBD's ability to engage it opens possibilities for treating inflammatory lung conditions.
Questions still open
- Would CBD be effective when administered after acute lung injury has already begun? What doses would be needed in humans? Could CBD benefit other inflammatory lung conditions through the same adenosine pathway? Would combining CBD with other adenosine-enhancing drugs improve outcomes?
Common questions
How does CBD reduce inflammation in the lungs?
Could CBD treat lung injuries in humans?
Read the original research
Cannabidiol, a non-psychotropic plant-derived cannabinoid, decreases inflammation in a murine model of acute lung injury: role for the adenosine A(2A) receptor.
European journal of pharmacology, 678(1-3), 78-85
Citation
Ribeiro, Alison; Ferraz-de-Paula, Viviane; Pinheiro, Milena L; Vitoretti, Luana B; Mariano-Souza, Domenica P; Quinteiro-Filho, Wanderley M; Akamine, Adriana T; Almeida, Vinícius I; Quevedo, João; Dal-Pizzol, Felipe; Hallak, Jaime E; Zuardi, Antônio W; Crippa, José A; Palermo-Neto, João. (2012). Cannabidiol, a non-psychotropic plant-derived cannabinoid, decreases inflammation in a murine model of acute lung injury: role for the adenosine A(2A) receptor.. European journal of pharmacology, 678(1-3), 78-85. https://doi.org/10.1016/j.ejphar.2011.12.043
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk
- How to Tell If Your Weed Is Moldy (and What Happens If You Use It)